Skip to main content
SpringerLink
Log in

Treatment of Acute Promyelocytic Leukemia by Retinoids

  • Chapter
Acute Promyelocytic Leukemia

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 313))

Abstract

We review the role of all-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL). The combination of ATRA and conventional anthracycline-ARA-C chemotherapy (CT) has clearly demonstrated its superiority over CT alone (in terms of relapse and survival) in newly diagnosed APL. Combination treatment probably also reduces the incidence of initial failures, and complete remission (CR) rates greater than 90% are now regularly reported in large multicenter trials. Some randomized studies strongly suggest that prolonged maintenance treatment (for 1 or 2 years) with ATRA and low-dose CT, and possibly very early introduction of anthracycline CT during induction treatment, may reduce the incidence of relapse. With those treatments, the relapse risk appears to be only 10%–15%, although it remains greater in patients who initially have high white blood cell counts (often associated with variant M3 morphology, short bcr3 isoform, etc.) and patients with residual disease detectable by RT-PCR at the end of consolidation courses. In those patients, addition of arsenic derivatives to induction or consolidation treatment (or both treatments together) may prove useful and is currently being tested. ATRA syndrome (now generally called APL differentiation syndrome, as it is also seen with arsenic derivatives) remains the major side effect of ATRA treatment. It occurs in 10%–15% of patients and is currently fatal in at least 10% of them. Rapid onset of CT or high dose steroids (or both) should improve its outcome. A sizeable proportion of APL patients who relapse after ATRA and CT can bedurably salvaged by the same treatment followed by allogeneic or autologous stem cell transplantation, provided the transplant (in the autologous setting) is RT-PCR-negative. However, in relapsing APL arsenic derivatives (mainly arsenic trioxide) are now considered to be the reference treatment. Some of the current issues with ATRA treatment in newly diagnosed APL include whether ATRA has a role during consolidation treatment and whether arabinoside (AraC) is required in addition to anthracyclines in the chemotherapy combined to ATRA.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33:451–458

    CAS  PubMed  Google Scholar 

  2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1980) A variant form of hypergranular promyelocytic leukemia (M3). Ann Intern Med 92:261

    CAS  PubMed  Google Scholar 

  3. Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD (1984) Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 76:827–841

    CAS  PubMed  Google Scholar 

  4. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A (1991) The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675–684

    PubMed  Google Scholar 

  5. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VV, Dmitrovsky E, Evans RM (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66:663–674

    CAS  PubMed  Google Scholar 

  6. Tallman MS, Brenner B, Serna JdL, Dombret H, Falanga A, Kwaan HC, Liebman H, Raffoux E, Rickles FR (2005) Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk Res 29:347–351

    PubMed  Google Scholar 

  7. Tallman MS (1999) The thrombophilic state in acute promyelocytic leukemia. Semin Thromb Hemost 25:209–215

    CAS  PubMed  Google Scholar 

  8. Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF (1973) Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 41:489–496

    CAS  PubMed  Google Scholar 

  9. Goldberg MA, Ginsburg D, Mayer RJ, Stone RM, Maguire M, Rosenthal DS, Antin JH (1987) Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 69:187–191

    CAS  PubMed  Google Scholar 

  10. Hoyle CF, Swirsky DM, Freedman L, Hayhoe FG (1988) Beneficial effect of heparin in the management of patients with APL. Br J Haematol 68:283–289

    CAS  PubMed  Google Scholar 

  11. Sanz MA, Jarque I, Martin G, Lorenzo I, Martinez J, Rafecas J, Pastor E, Sayas MJ, Sanz G, Gomis F (1988) Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer 61:7–13

    CAS  PubMed  Google Scholar 

  12. Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD (1989) Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 73:1116–1122

    CAS  PubMed  Google Scholar 

  13. Fenaux P, Tertian G, Castaigne S, Tilly H, Leverger G, Guy H, Bordessoule D, Leblay R, Le Gall E, Colombat P, et al (1991) A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. J Clin Oncol 9:1556–1561

    CAS  PubMed  Google Scholar 

  14. Fenaux P, Degos L (1991) Treatment of acute promyelocytic leukemia with all-trans retinoic acid. Leuk Res 15:655–657

    CAS  PubMed  Google Scholar 

  15. Marty M, Ganem G, Fischer J, Flandrin G, Berger R, Schaison G, Degos L, Boiron M (1984) Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin (in French). Nouv Rev Fr Hematol 26:371–378

    CAS  PubMed  Google Scholar 

  16. Head DR, Kopecky KJ, Weick J, Files FC, Ryan D, Foucar K, Montiel Bickers J, Fishleder A, Miller M, et al (1995) Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86:1717–1728

    CAS  PubMed  Google Scholar 

  17. Avvisatti G, Petti MC, Lo-Coco F, et al (2002) Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 100:3141–3146

    Google Scholar 

  18. Arlin Z, Kempin S, Mertelsmann R, Gee T, Higgins C, Jhanwar S, Chaganti RS, Clarkson B (1984) Primary therapy of acute promyelocytic leukemia: results of amsacrine-and daunorubicin-based therapy. Blood 63:211–212

    CAS  PubMed  Google Scholar 

  19. Lengfelder E, Reichert A, Hehlmann R (1997) Effect of high dose AraCX in APL. Blood 92Suppl

    Google Scholar 

  20. Bassan R, Battista R, Viero P, d’Emilio A, Buelli M, Montaldi A, Rambaldi A, Tremul L, Dini E, Barbui T (1995) Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. Leukemia 9:238–243

    CAS  PubMed  Google Scholar 

  21. Reference deleted in proof

    Google Scholar 

  22. Cordonnier C, Vernant JP, Brun B, Heilmann MG, Kuentz M, Bierling P, Farcet JP, Rodet M, Duedari N, Imbert M, et al (1985) Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 55:18–25

    CAS  PubMed  Google Scholar 

  23. Kantarjian HM, Keating MJ, Walters RS, Estey EH, McCredie KB, Smith TL, Dalton WT Jr, Cork A, Trujillo JM, Freireich EJ (1986) Acute promyelocytic leukemia. MD Anderson Hospital experience. Am J Med 80:789–797

    CAS  PubMed  Google Scholar 

  24. Fenaux P, Pollet J, Vandebossche L, et al (1991) Treatment of acute promyelocytic leukemia: a report of 70 cases. Leuk Lymphoma 4:249–256

    Google Scholar 

  25. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567–572

    CAS  PubMed  Google Scholar 

  26. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L (1990) All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704–1709

    CAS  PubMed  Google Scholar 

  27. Degos L, Chomienne C, Daniel MT, Berger R, Dombret H, Fenaux P, Castaigne S (1990) Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. Lancet 336:1440–1441

    CAS  PubMed  Google Scholar 

  28. Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C, Wang W, Zu WY, Yao XZ, Ling BJ (1991) A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78:1413–1419

    CAS  PubMed  Google Scholar 

  29. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, et al (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385–1393

    PubMed  Google Scholar 

  30. Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, Castaigne S, Degos L (1990) All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood 76:1710–1717

    CAS  PubMed  Google Scholar 

  31. Elliott S, Taylor K, White S, Rodwell R, Marlton P, Meagher D, Wiley J, Taylor D, Wright S, Timms P (1992) Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood 79:1916–1919

    CAS  PubMed  Google Scholar 

  32. Ohashi H, Ichikawa A, Takagi N, Hotta T, Naoe T, Ohno R, Saito H (1992) Remission induction of acute promyelocytic leukemia by all-trans-retinoic acid: molecular evidence of restoration of normal hematopoiesis after differentiation and subsequent extinction of leukemic clone. Leukemia 6:859–862

    CAS  PubMed  Google Scholar 

  33. Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, Lamy T, Tilly H, Guerci A, Maloisel F, et al (1992) All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 80:2176–2181

    CAS  PubMed  Google Scholar 

  34. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr (1992) The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med 117:292–296

    CAS  PubMed  Google Scholar 

  35. Fenaux P, Degos L (1996) Treatment of acute promyelocytic leukaemia. Baillieres Clin Haematol 9:107–128

    CAS  PubMed  Google Scholar 

  36. Fenaux P, Wattel E, Archimbaud E, Sanz M, Hecquet B, Fegueux N, Guerci A, Link H, Fey M, Castaigne S, et al (1994) Prolonged follow-up confirms that all-trans retinoic acid followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia. The French APL Group. Blood 84:666–667

    CAS  PubMed  Google Scholar 

  37. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D, et al (1993) Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 82:3241–3249

    CAS  PubMed  Google Scholar 

  38. Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X, Sanz M, Link H, Maloisel F, Gardin C, Bordessoule D, Stoppa AM, Sadoun A, Muus P, Wandt H, Mineur P, Whittaker JA, Fey M, Daniel MT, Castaigne S, Degos L (2000) Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia 14:1371–1377

    CAS  PubMed  Google Scholar 

  39. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH (1997) All-transretinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021–1028

    CAS  PubMed  Google Scholar 

  40. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L (1999) A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 94:1192–1200

    CAS  PubMed  Google Scholar 

  41. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH (2002) All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100:4298–4302

    CAS  PubMed  Google Scholar 

  42. Girmenia C, Latagliata R, Tosti S, Morano SG, Celesti F, Coppola L, Spadea A, Breccia M, Battistini R, Tafuri A, Cimino G, Mandelli F, Alimena G (1999) Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy. Leukemia 13:514–517

    CAS  PubMed  Google Scholar 

  43. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH (1999) Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 93:4131–4143

    CAS  PubMed  Google Scholar 

  44. De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, Gardembas M, Stamatoulas A, Conde E, Guerci A, Gardin C, Geiser K, Makhoul DC, Reman O, de la Serna J, Lefrere F, Chomienne C, Chastang C, Degos L, Fenaux P (1998) Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 92:2712–2718

    PubMed  Google Scholar 

  45. Castaigne S, Lefebvre P, Chomienne C, Suc E, Rigal-Huguet F, Gardin C, Delmer A, Archimbaud E, Tilly H, Janvier M, et al (1993) Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia. Blood 82:3560–3563

    CAS  PubMed  Google Scholar 

  46. Mahmoud HH, Hurwitz CA, Roberts WM, Santana VM, Ribeiro RC, Krance RA (1993) Tretinoin toxicity in children with acute promyelocytic leukaemia. Lancet 342:1394–1395

    CAS  PubMed  Google Scholar 

  47. Sanz MA, Lo-Coco F (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247–1253

    CAS  PubMed  Google Scholar 

  48. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M (1997) Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 15:483–490

    CAS  PubMed  Google Scholar 

  49. Cornic M, Delva L, Guidez F, Balitrand N, Degos L, Chomienne C (1992) Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res 52:3329–3334

    CAS  PubMed  Google Scholar 

  50. Muindi J, Frankel SR, Miller WH Jr, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrell RP Jr (1992) Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood 79:299–303

    CAS  PubMed  Google Scholar 

  51. Adamson PC, Bailey J, Pluda J, Poplack DG, Bauza S, Murphy RF, Yarchoan R, Balis FM (1995) Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol 13:1238–1241

    CAS  PubMed  Google Scholar 

  52. Sanz A, Martin G, Gonzalez M, et al (2004) Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study par the PETHEMA group. Blood 103:1237–1243

    CAS  PubMed  Google Scholar 

  53. Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama K, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake S, Suzushima H, Emi N, Ohno R (1998) Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 16:78–85

    CAS  PubMed  Google Scholar 

  54. Claxton DF, Reading CL, Nagarajan L, Tsujimoto Y, Andersson BS, Estey E, Cork A, Huh YO, Trujillo J, Deisseroth AB (1992) Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood 80:582–586

    CAS  PubMed  Google Scholar 

  55. Paietta E, Andersen J, Gallagher R, Bennett J, Yunis J, Cassileth P, Rowe J, Wiernik PH (1994) The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. Leukemia 8:1108–1112

    CAS  PubMed  Google Scholar 

  56. Guglielmi C, Martelli MP, Diverio D, Fenu S, Vegna ML, Cantu-Rajnoldi A, Biondi A, Cocito MG, Del Vecchio L, Tabilio A, Avvisati G, Basso G, Lo Coco F (1998) Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br J Haematol 102:1035–1041

    CAS  PubMed  Google Scholar 

  57. Murray CK, Estey E, Paietta E, Howard RS, Edenfield WJ, Pierce S, Mann KP, Bolan C, Byrd JC (1999) CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol 17:293–297

    CAS  PubMed  Google Scholar 

  58. Cassinat B, Chevret S, Zassadowski F, Balitrand N, Guillemot I, Menot ML, Degos L, et al (2001) In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome. Blood 98:2862–2864

    PubMed  Google Scholar 

  59. Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP Jr, Miller WH Jr (2001) Prognostic significance of minimal residual disease detection and PML/RAR-isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 98:2651–2656

    CAS  PubMed  Google Scholar 

  60. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi A, Lo Coco F (1998) Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter “AIDA” trial. GIMEMAAIEOP Multicenter “AIDA” Trial. Blood 92:784–789

    CAS  PubMed  Google Scholar 

  61. Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain JD, Fenaux P, Degos L, Vidaud M, Chomienne C (2000) Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RTPCR. Leukemia 14:324

    CAS  PubMed  Google Scholar 

  62. Visani G, Buonamici S, Malagola M, Isidori A, Piccaluga PP, Martin G, Ottaviani E, Grafone T, Baccarani M, Tura S (2000) Pulsed ATRA as single therapy restores long-term remission PML-RARalpha-positive acute promyelocytic leukemia patient real time quantification of minimal residual disease. A pilot study. Leukemia 15:1696–1700

    Google Scholar 

  63. Gallagher RE, Yeap BY, Bi W, et al (2003) Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 101:2521–2528

    CAS  PubMed  Google Scholar 

  64. Bolufer P, Barragan E, Sanz MA, Martin G, Bornstein R, Colomer D, Delgado MD, Gonzalez M, Marugan I, Roman J, Gomez MT, Anguita E, Diverio D, Chomienne C, Briz M (1998) Preliminary experience in external quality control of RT-PCR PML-RAR alpha detection in promyelocytic leukemia. Leukemia 12:2024–2028

    CAS  PubMed  Google Scholar 

  65. Evans GD, Grimwade DJ (1999) Extramedullary disease in acute promyelocytic leukemia. Leuk Lymphoma 33:219–229

    CAS  PubMed  Google Scholar 

  66. de Botton S, Sanz M, Chevret S, et al (2006) Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 20:35–41

    PubMed  Google Scholar 

  67. Lo-Coco F, Vignetti M, Avvisatti G, et al (2004) Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation: results of the AIDA-2000 trial of the Italian GIMEMA group. Blood 104Suppl 1 Abstr 392

    Google Scholar 

  68. Lengfelder E, Reichert A, Schoch C, et al (2000) Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 14:1362–1370

    CAS  PubMed  Google Scholar 

  69. Warrell RP Jr, Maslak P, Eardley A, Heller G, Miller WH Jr, Frankel SR (1994) Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 8:929–933

    PubMed  Google Scholar 

  70. Delva L, Cornic M, Balitrand N, Guidez F, Miclea JM, Delmer A, Teillet F, Fenaux P, Castaigne S, Degos L, et al (1993) Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 82:2175–2181

    CAS  PubMed  Google Scholar 

  71. Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, Vekhoff A, Sadoun A, Stamatoullas A, Fegueux N, Maloisel F, Cahn JY, Reman O, Gratecos N, Berthou C, Huguet F, Kotoucek P, Travade P, Buzyn A, de Revel T, Vilque JP, Naccache P, Chomienne C, Degos L, Fenaux P (2000) Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia. Leukemia 14:1006–1013

    CAS  PubMed  Google Scholar 

  72. de Botton S, Fawaz A, Chevret S, et al (2005) Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 23:120–126

    PubMed  Google Scholar 

  73. Ding W, Li YP, Nobile LM, Grills G, Carrera I, Paietta E, Tallman MS, Wiernik PH, Gallagher RE (1998) Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 92:1172–1183

    CAS  PubMed  Google Scholar 

  74. Douer D, Estey E, Santillana S, Bennett JM, Lopez-Bernstein G, et al (2001) Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. Blood 97:73–80

    CAS  PubMed  Google Scholar 

  75. Mehta K, Sadeghi T, McQueen T, Lopez-Berestein G (1994) Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid. Leuk Res 18:587–596

    CAS  PubMed  Google Scholar 

  76. Soignet SL, Benedetti F, Fleischauer A, Parker BA, Truglia JA, Ra Crisp M, Warrell RP Jr (1998) Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemia. Leukemia 12:1518–1521

    CAS  PubMed  Google Scholar 

  77. Miller WH, Jakubowski A, Tong WP, Miller VA, Rigas JR, Benedetti F, Gill GM, Truglia JA, Ulm E, Shirley M (1995) 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood 85:3021

    CAS  PubMed  Google Scholar 

  78. Tobita T, Takeshita A, Kitamura K, Ohnishi K, Yanagi M, Hiraoka A, Karasuno T, Takeuchi M, Miyawaki S, Ueda R, Naoe T, Ohno R (1997) Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 90:967–973

    CAS  PubMed  Google Scholar 

  79. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90:1621–1625

    CAS  PubMed  Google Scholar 

  80. Kosugi H, Towatari M, Hatano S, Kitamura K, Kiyoi H, Kinoshita T, Tanimoto M, Murate T, Kawashima K, Saito H, Naoe T (1999) Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia 13:1316–1324

    CAS  PubMed  Google Scholar 

  81. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA (2000) Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 6:372–380

    CAS  PubMed  Google Scholar 

  82. Petti MC, Pinazzi MB, Diverio D, Romano A, Petrucci MT, De Santis S, Meloni G, Tafuri A, Mandelli F, LoCoco F (2001) Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). Br J Haematol 115:63–65

    CAS  PubMed  Google Scholar 

  83. Yang Y, Liu T, Liang Y, Qin P, Yuan S (1994) Study on anti-leukemic effect of tanshinone IIA in vitro and in vivo to acute promyelocytic leukemia. Blood 94Suppl 1

    Google Scholar 

  84. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354–3360

    CAS  PubMed  Google Scholar 

  85. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, De-Blasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341–1348

    CAS  PubMed  Google Scholar 

  86. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang T, Waxman S, Wang ZY, Chen SJ, et al (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94:3315–3324

    CAS  PubMed  Google Scholar 

  87. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R, Warrell RP Jr (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852–3860

    CAS  PubMed  Google Scholar 

  88. Leoni F, Gianfaldoni G, Annunziata M, Fanci R, Ciolli S, Nozzoli C, Ferrara F (2002) Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. Haematologica 87:485–489

    CAS  PubMed  Google Scholar 

  89. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Takeshita A, Sugiyama S, Satoh H, Terada H, Ohno R (2000) Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann InternMed 133:881–885

    CAS  Google Scholar 

  90. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, DiPersio JF (2001) Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98:266–271

    CAS  PubMed  Google Scholar 

  91. Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R (2001) Arsenic trioxide-and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. AmJHematol 66:274–279

    CAS  Google Scholar 

  92. Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM, Li XS, Wu W, Xiong SM, Zhao WL, Tang W, Wu F, Liu YF, Niu C, Wang ZY, Chen SJ, Chen Z (2001) Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 15:735–741

    CAS  PubMed  Google Scholar 

  93. Roberts TF, Sprague K, Schenkein D, Miller KB, Relias V (2000) Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction. Blood 96:4000–4001

    CAS  PubMed  Google Scholar 

  94. Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA, Ellison R, Warrell RP Jr (2000) Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 18:2620–2625

    CAS  PubMed  Google Scholar 

  95. Che-Pin L, Huang MJ, Chang IY, Lin WY, Sheu YT (2000) Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia. Leuk Lymphoma 38:195–198

    Google Scholar 

  96. Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S, Wiernik PH, Chiaramida S (2001) Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 97:1514–1516

    CAS  PubMed  Google Scholar 

  97. Yip SF, Yeung YM, Tsui EY (2002) Severe neurotoxicity following arsenic therapy for acute promyelocytic leukemia: potentiation by thiamine deficiency. Blood 99:3481–3482

    CAS  PubMed  Google Scholar 

  98. Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR, Chen SS (2002) Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 99:3136–3143

    CAS  PubMed  Google Scholar 

  99. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH, Waxman S (2001) Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 97:264–269

    CAS  PubMed  Google Scholar 

  100. Au WY, Chim CS, Lie AK, Liang R, Kwong YL (2002) Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 117:130–132

    CAS  PubMed  Google Scholar 

  101. Marasca R, Zucchini P, Galimberti S, Leonardi G, Vaccari P, Donelli A, Luppi M, Petrini M, Torelli G (1999) Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. Haematologica 84:963–968

    CAS  PubMed  Google Scholar 

  102. Wang ZG, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP Jr, Pandolfi PP (1998) Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 92:1497–1504

    CAS  PubMed  Google Scholar 

  103. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94:2102–2111

    CAS  PubMed  Google Scholar 

  104. Davison K, Mann KK, Miller WH Jr (2002) Arsenic trioxide: mechanisms of action. Semin Hematol 39:3–7

    CAS  PubMed  Google Scholar 

  105. Hong SH, Yang Z, Privalsky ML (2001) Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia. Mol Cell Biol 21:7172–7182

    CAS  PubMed  Google Scholar 

  106. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP Jr, Rafii S (2000) Arsenic trioxide induces dose-and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96:1525–1530

    CAS  PubMed  Google Scholar 

  107. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89:3345–3353

    Google Scholar 

  108. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Rowe JM, Francois C, Larson RS, Wiernik PH (2000) Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 95:90–95

    CAS  PubMed  Google Scholar 

  109. Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, et al (1995) All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 85:1202–1206

    CAS  PubMed  Google Scholar 

  110. Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA, Warrell RP Jr (1994) Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843–3849

    CAS  PubMed  Google Scholar 

  111. Ko BS, Tang JL, Chen YC, Yao M, Wang CH, Shen MC, Tien HF (1999) Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia-the occurrence of retinoic acid syndrome is a risk factor. Leukemia 13:1406–1408

    CAS  PubMed  Google Scholar 

  112. Dubois C, Schlageter MH, de Gentile A, Balitrand N, Toubert ME, Krawice I, Fenaux P, Castaigne S, Najean Y, Degos L, et al (1994) Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 8:1750–1757

    CAS  PubMed  Google Scholar 

  113. Dubois C, Schlageter MH, de Gentile A, Guidez F, Balitrand N, Toubert ME, Krawice I, Fenaux P, Castaigne S, Najean Y, et al (1994) Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells. Blood 83:3264–3270

    CAS  PubMed  Google Scholar 

  114. Larson RS, Brown DC, Sklar LA (1997) Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2. Blood 90:2747–2756

    CAS  PubMed  Google Scholar 

  115. Visani G, Tosi P, Cenacchi A, Manfroi S, Gamberi B, Ottaviani E, Tura S (1994) Pre-treatment with all-trans retinoic acid accelerates polymorphonuclear recovery after chemotherapy in patients with acute promyelocytic leukemia. Leuk Lymphoma 15:143–147

    CAS  PubMed  Google Scholar 

  116. De Botton S, Coitteux V, Chevret S, Dombret H, Sanz M, SanMiguel J, Caillot D, et al (2001) Early onset chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL). Results of a randomized study. Blood 98:766a

    Google Scholar 

  117. Stadler M, Ganser A, Hoelzer D (1994) Acute promyelocytic leukemia. N Engl J Med 330:140–141

    CAS  PubMed  Google Scholar 

  118. Tapiovaara H, Matikainen S, Hurme M, Vaheri A (1994) Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors. Blood 83:1883–1891

    CAS  PubMed  Google Scholar 

  119. de Lacerda JF, do Carmo JA, Guerra ML, Geraldes J, de Lacerda JM (1993) Multiple thrombosis in acute promyelocytic leukaemia after tretinoin. Lancet 342:114–115

    PubMed  Google Scholar 

  120. Hashimoto S, Koike T, Tatewaki W, Seki Y, Sato N, Azegami T, Tsukada N, Takahashi H, Kimura H, Ueno M, et al (1994) Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 8:1113–1115

    CAS  PubMed  Google Scholar 

  121. Torromeo C, Latagliata R, Avvisati G, Petti MC, Mandelli F (1999) Coronaric thrombotic events in acute promyelocytic leukemia during all-trans retinoic acid treatment: a role for adhesion molecules overexpression? Leukemia 13:312–313

    CAS  PubMed  Google Scholar 

  122. Akiyama H, Nakamura N, Nagasaka S, Sakamaki H, Onozawa Y (1992) Hypercalcaemia due to all-trans retinoic acid. Lancet 339:308–309

    CAS  PubMed  Google Scholar 

  123. Hakimian D, Tallman MS, Zugerman C, Caro WA (1993) Erythema nodosum associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 7:758–759

    CAS  PubMed  Google Scholar 

  124. Koike T, Tatewaki W, Aoki A, Yoshimoto H, Yagisawa K, Hashimoto S, Furukawa T, Saitoh H, Takahashi M, Yang LB, et al (1992) Brief report: severe symptoms of hyperhistaminemia after the treatment of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 327:385–387

    CAS  PubMed  Google Scholar 

  125. Iwakiri R, Inokuchi K, Dan K, Nomura T (1994) Marked basophilia in acute promyelocytic leukaemia treated with all-trans retinoic acid: molecular analysis of the cell origin of the basophils. Br J Haematol 86:870–872

    CAS  PubMed  Google Scholar 

  126. Miranda N, Oliveira P, Frade MJ, Melo J, Marques MS, Parreira A (1994) Myositis with tretinoin. Lancet 344:1096

    CAS  PubMed  Google Scholar 

  127. Tomas JF, Escudero A, Fernandez-Ranada JM (1994) All-trans retinoic acid treatment and Sweet syndrome. Leukemia 8:1596

    CAS  PubMed  Google Scholar 

  128. Arun B, Berberian B, Azumi N, Frankel SR, Luksenburg H, Freter C (1998) Sweet’s syndrome during treatment with all-trans retinoic acid in a patient with acute promyelocytic leukemia. Leuk Lymphoma 31:613–615

    CAS  PubMed  Google Scholar 

  129. Levy V, Jaffarbey J, Aouad K, Zittoun R (1998) Fournier’s gangrene during induction treatment of acute promyelocytic leukemia, a case report. Ann Hematol 76:91–92

    CAS  PubMed  Google Scholar 

  130. Mori A, Tamura S, Katsuno T, Nishimura Y, Itoh T, Saheki K, Takatsuka H, Wada H, Fujimori Y, Okamoto T, Takemoto Y, Kakishita E (1999) Scrotal ulcer occurring in patients with acute promyelocytic leukemia during treatment with all-trans retinoic acid. Oncol Rep 6:55–58

    CAS  PubMed  Google Scholar 

  131. Kentos A, LeMoine F, Crenier L, Capel P, Meyer S, Muus P, Mandelli F, Feremans W (1997) All-trans retinoic acid induced thrombocytosis in a patient with acute promyelocytic leukaemia. Br J Haematol 97:685

    CAS  PubMed  Google Scholar 

  132. Paydas S, Sahin B, Zorludemir S, Hazar B (1998) All trans retinoic acid as the possible cause of necrotizing vasculitis. Leuk Res 22:655–657

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’Hématologie Clinique, Hôpital Avicenne, Paris 13 University, 93000, Bobigny, France

    P. Fenaux

  2. Institute of Hematology, Shangai, China

    Z. Z. Wang

  3. Institut d’Hématologie, Hôtal Saint Louis, Paris, France

    L. Degos

Authors
  1. P. Fenaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Z. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Degos
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, Sloan-Kettering-Institute, 1275 York Avenue, New York, New York, 10021, USA

    Pier Paolo Pandolfi MD, Ph.D.

  2. The Scripps Research Institute, 10550 North Torreye Pines Road, La Jolla, CA, 92037, USA

    Peter K. Vogt Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fenaux, P., Wang, Z.Z., Degos, L. (2007). Treatment of Acute Promyelocytic Leukemia by Retinoids. In: Pandolfi, P.P., Vogt, P.K. (eds) Acute Promyelocytic Leukemia. Current Topics in Microbiology and Immunology, vol 313. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34594-7_7

Download citation

Publish with us

Policies and ethics

Search

Navigation